Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Antiva Biosciences

Request full access

A biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection

Redwood City, United StatesFounded 2012Biotech & Life Sciences

About Antiva Biosciences

Antiva Bio is a healthcare startup that focuses on the development of innovative topical treatments for pre-cancerous cervical lesions and the Human Papillomavirus (HPV) infections that cause these lesions. The company's primary market is women who are diagnosed with HPV infections and pre-cancerous cervical lesions.

Currently, there is no treatment for HPV infection, and women are often left in a state of uncertainty, waiting to see if their infection clears up on its own or progresses to a more severe disease. Antiva Bio aims to change this by developing a first-of-its-kind therapy that women can use to treat themselves at home as soon as their infection is diagnosed.

This therapy also offers a non-surgical alternative for women whose disease has progressed further. This means that Antiva Bio's business model is centered around providing a simple, convenient, and non-invasive solution to a global health issue.

The company generates revenue by developing and selling these novel therapies. Their experienced team is committed to improving health outcomes and access to care worldwide, aligning with the World Health Organization’s global Cervical Cancer Elimination Initiative.

In summary, Antiva Bio is a pioneering healthcare startup that is developing innovative, home-based, non-surgical treatments for HPV infections and pre-cancerous cervical lesions, with a mission to improve women's health outcomes globally.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
29.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Femtech, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Apr 2023 $53M $212M Canaan · Lumira Ventures · BioImpact Capital · GV ↗
SERIES DOther financing Nov 2021 $31M $124M Canaan · Brace Pharma · Gaingels · HBM Healthcare Investments —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Antiva Biosciences website traffic

Latest recorded traffic for Antiva Biosciences is 2.7K monthly website visits, up 50% over the last three months. Antiva Biosciences's team declined 30.8% over the past year.

Latest monthly visits2.7K 3-month web change+50% 1-year team growth-30.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Antiva Biosciences in the Redwood City ecosystem

Live from Dealroom

The Antiva Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Canaan
  • Sofinnova Investments
  • Wende Hutton

Series B and later15 investors entered at this stage

  • Brace Pharma
  • Osage University Partners
  • Alexandria Venture Investments
  • Hillhouse Capital
  • Sirona Capital
  • Lumira Ventures
  • Adjuvant Capital
  • Gaingels
  • HBM Healthcare Investments
  • Dong-A ST
  • Mana Ventures
  • Avestria Ventures
  • MPM BioImpact
  • BioImpact Capital
  • GV
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Antiva Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Antiva Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.